

MAINE STATE LEGISLATURE

The following document is provided by the
LAW AND LEGISLATIVE DIGITAL LIBRARY
at the Maine State Law and Legislative Reference Library
<http://legislature.maine.gov/lawlib>



Reproduced from electronic originals
(may include minor formatting differences from printed original)



129th MAINE LEGISLATURE

FIRST REGULAR SESSION-2019

Legislative Document

No. 1460

S.P. 445

In Senate, April 2, 2019

An Act To Support Collection and Proper Disposal of Unwanted Drugs

Reference to the Committee on Environment and Natural Resources suggested and ordered printed.

A handwritten signature in black ink, appearing to read 'D M Grant'.

DAREK M. GRANT
Secretary of the Senate

Presented by Senator GRATWICK of Penobscot.
Cosponsored by Representative HYMANSON of York and
Senators: BLACK of Franklin, CLAXTON of Androscoggin, DAVIS of Piscataquis, DILL of
Penobscot, President JACKSON of Aroostook, SANBORN, L. of Cumberland, VITELLI of
Sagadahoc, Representative: MADIGAN of Waterville.

1 **Be it enacted by the People of the State of Maine as follows:**

2 **Sec. 1. 22 MRSA §2700, sub-§8** is enacted to read:

3 **8. Drug take-back stewardship program participation.** Nothing in this section
4 prohibits a law enforcement agency from participating as an authorized collector in a
5 drug take-back stewardship program implemented under Title 38, section 1611.

6 **Sec. 2. 38 MRSA §1611** is enacted to read:

7 **§1611. Drug take-back stewardship program**

8 **1. Definitions.** As used in this section, unless the context otherwise indicates, the
9 following terms have the following meanings.

10 **A. "Authorized collector" means:**

11 (1) A person, company, corporation or other entity that is registered with the
12 United States Department of Justice, Drug Enforcement Administration to collect
13 controlled substances for the purposes of safe disposal and destruction;

14 (2) A law enforcement agency; or

15 (3) A person, company, corporation or other entity authorized by the department
16 to provide alternative collection methods for covered drugs that are not controlled
17 substances.

18 **B. "Brand" means a name, symbol, word or mark that identifies a covered drug,**
19 **rather than its components, and attributes a covered drug to the owner of the brand.**

20 **C. "Closed-shop pharmacy" means a pharmacy that purchases drugs for and**
21 **dispenses drugs to a limited, institutional patient population.**

22 **D. "Covered drug" means any substance recognized as a drug under 21 United States**
23 **Code, Section 321(g)(1), as amended, and any regulations adopted pursuant to that**
24 **provision that is sold, offered for sale or dispensed in the State, whether directly or**
25 **through a wholesaler, in any form, including prescription and nonprescription drugs,**
26 **drugs in medical devices and combination products, brand and generic drugs and**
27 **drugs for veterinary use.**

28 **(1) "Covered drug" does not include:**

29 **(a) Vitamins or supplements;**

30 **(b) Herbal-based remedies and homeopathic drugs, products or remedies;**

31 **(c) Cosmetics, soap with or without germicidal agents, laundry detergent,**
32 **bleach, household cleaning products, shampoo, sunscreen, toothpaste, lip**
33 **balm, antiperspirant or other personal care products that are regulated as both**
34 **cosmetics and nonprescription drugs under the federal Food, Drug, and**
35 **Cosmetic Act;**

36 **(d) Pet pesticide products contained in pet collars, powders, shampoos,**
37 **topical applications or other forms;**

1 (e) Drugs that are biological products as defined in 21 Code of Federal
2 Regulations, Section 600.3(h) if the manufacturer provides a program to take
3 back that drug;

4 (f) Drugs for which a manufacturer provides a program to take back those
5 drugs as part of a United States Department of Health and Human Services,
6 Food and Drug Administration managed risk evaluation and mitigation
7 strategy;

8 (g) Emptied syringes or emptied medical devices or the component parts or
9 accessories of those products or devices; and

10 (h) Drugs that are used solely in a clinical setting.

11 E. "Drug take-back stewardship organization" or "stewardship organization" means a
12 corporation, nonprofit organization or other legal entity created by one or more
13 manufacturers to implement a drug take-back stewardship program.

14 F. "Drug take-back stewardship plan" or "plan" means a plan designed by a
15 manufacturer or drug take-back stewardship organization for the establishment of a
16 drug take-back stewardship program.

17 G. "Drug take-back stewardship program" or "stewardship program" means a system
18 implemented for the collection, transportation and disposal of covered drugs in
19 accordance with a drug take-back stewardship plan approved by the department under
20 subsection 4.

21 H. "Mandatory pharmacy collector" means a pharmacy registered with the Maine
22 Board of Pharmacy that is part of a group of 10 or more establishments that conduct
23 business under the same name or operate under a common ownership or management
24 or pursuant to a franchise agreement with the same franchisor and a nonresident
25 pharmacy registered with the Maine Board of Pharmacy that provides covered drugs
26 to residents in the State by mail. "Mandatory pharmacy collector" does not include a
27 closed-shop pharmacy.

28 I. "Manufacturer" means an entity that:

29 (1) Has legal ownership of the brand of a covered drug sold in or into the State;

30 (2) Imports a covered drug branded by a person that meets the requirements of
31 subparagraph (1) and has no physical presence in the United States; or

32 (3) Sells a covered drug in the State at wholesale or retail, does not have legal
33 ownership of the brand of the covered drug and elects to fulfill the
34 responsibilities of the manufacturer for that covered drug.

35 J. "Operator" means a manufacturer or drug take-back stewardship organization that
36 implements and operates a drug take-back stewardship program.

37 **2. Drug take-back stewardship program.** A manufacturer shall:

38 A. Individually or jointly with one or more manufacturers, operate a drug take-back
39 stewardship program approved by the department;

1 B. Enter into an agreement with a drug take-back stewardship organization to
2 operate a drug take-back stewardship program; or

3 C. Enter into an agreement with the department to operate a drug take-back
4 stewardship program on behalf of the manufacturer.

5 **3. Submittal of drug take-back stewardship plan.** A manufacturer, individually or
6 jointly with one or more manufacturers, or a drug take-back stewardship organization
7 contracted by one or more manufacturers shall submit to the department a proposed drug
8 take-back stewardship plan. The plan must, at a minimum, include:

9 A. A certification that the drug take-back stewardship program will accept all
10 covered drugs regardless of who produced them;

11 B. Contact information for the person submitting the drug take-back stewardship
12 plan with whom the department shall direct all inquiries related to the plan and a
13 listing of participating manufacturers with contact information for each participating
14 manufacturer;

15 C. A description of how the drug take-back stewardship program will provide free,
16 convenient and ongoing collection of covered drugs to all persons seeking to dispose
17 of covered drugs and how the collection will be geographically distributed in a way
18 to ensure access in rural and underserved areas based on the use of geographic
19 information modeling;

20 D. A description of the collection methods to be used to ensure that covered drugs
21 will be collected by authorized collectors;

22 E. A listing of authorized collectors and collection sites;

23 F. Information on how covered drugs will be safely and securely tracked and handled
24 from collection through final disposition and policies to ensure security and
25 compliance with all applicable federal and state laws, rules and regulations including,
26 but not limited to, 21 Code of Federal Regulations, Section 1317.90, which requires
27 disposal and destruction at a licensed waste disposal facility that renders drugs
28 nonretrievable;

29 G. A description of how the collection system will be designed and monitored to
30 prevent tampering;

31 H. A description of how the amount of covered drugs collected and disposed of will
32 be measured;

33 I. A description of the education and outreach materials that will be used to
34 encourage consumer participation, including, but not limited to, messaging that is
35 understood by a diverse audience, a publicly accessible website with information for
36 both authorized collectors and consumers about the drug take-back stewardship
37 program and printed materials for collection sites including brochures and signage.
38 The education and outreach efforts must ensure that 60% of consumers are aware of
39 the stewardship program after one year of stewardship program implementation, 70%
40 after 2 years and 90% after 4 years;

1 J. A description of the performance goals established to measure the success of the
2 drug take-back stewardship program and a description of how the stewardship
3 program will be designed to meet or exceed those goals; and

4 K. Information on how the drug take-back stewardship program will be financed in
5 accordance with subsection 5.

6 **4. Approval of drug take-back stewardship plan.** Within 20 business days after
7 receipt of a proposed drug take-back stewardship plan under subsection 3, the department
8 shall review the plan and approve, approve with conditions or deny the plan. The
9 department shall notify the submitter in writing of the department's determination and, if
10 the plan is approved with conditions or denied, the notification must include the reasons
11 for the determination.

12 A. A manufacturer or drug take-back stewardship organization whose drug take-back
13 stewardship plan is denied shall submit a revised plan to the department within 60
14 days after receiving a notice of denial. If the department denies the subsequent
15 proposal, the manufacturer or manufacturers participating in the proposed drug take-
16 back stewardship program are out of compliance with this section and subject to the
17 enforcement provisions under this section. The department may hold a public hearing
18 prior to making a decision to approve, approve with conditions or deny a proposed
19 plan.

20 B. A manufacturer who begins to offer a covered drug in the State after the effective
21 date of this section shall provide to the department evidence of joining an existing
22 drug take-back stewardship program or submit a proposed drug take-back
23 stewardship plan within 30 days after the manufacturer's initial offer for sale of a
24 covered drug.

25 C. Prior to implementing a change to an approved drug take-back stewardship plan,
26 an operator shall submit the proposed change to the department for review. If a
27 change is not substantive, such as the addition of or a change to a collection site or
28 the addition of a manufacturer to the drug take-back stewardship program, approval
29 by the department is not needed, but the operator shall inform the department of the
30 change within 14 days of implementing the change. The department shall review plan
31 amendments in accordance with this section.

32 D. At any time, the department may require changes to a drug take-back stewardship
33 plan or implementation of a plan to meet the requirements of this subsection.

34 **5. Costs.** A manufacturer, individually or jointly with one or more manufacturers,
35 shall pay all administrative and operational costs associated with the manufacturer's drug
36 take-back stewardship program, including, but not limited to:

37 A. The cost of collecting covered drugs from mandatory pharmacy collectors and
38 authorized collectors, transporting covered drugs to disposal locations and disposing
39 of covered drugs;

40 B. Costs related to working with authorized collectors to develop a readily
41 recognizable, consistent design of collection receptacles, as well as clear,
42 standardized instructions for consumers on the use of collection receptacles. The

1 department may provide guidance to manufacturers on the development of the
2 instructions and design;

3 C. Costs incurred by the State in the administration and enforcement of the drug
4 take-back stewardship program; and

5 D. All costs associated with drug take-back stewardship program effectiveness and
6 assessments under this section.

7 When more than one manufacturer participates in a drug take-back stewardship program,
8 the costs of administration and enforcement must be fairly and reasonably allocated so
9 that the portion of costs allocated to each manufacturer is reasonably related to the market
10 share of covered drugs that manufacturer sells in the State.

11 Disposal of a covered drug under a drug take-back stewardship program must be free to
12 consumers. A manufacturer may not charge a point-of-sale fee to consumers, or a fee
13 that could be passed on to consumers, to recoup the cost of implementing the stewardship
14 program.

15 **6. Confidential information.** Proprietary information submitted to the department
16 in a drug take-back stewardship plan, in an amendment to a plan or pursuant to reporting
17 requirements of this section that is identified by the submitter as proprietary information
18 is confidential and must be handled by the department in the same manner as confidential
19 information is handled under section 1310-B. As used in this subsection, "proprietary
20 information" means information that is a trade secret or production, commercial or
21 financial information the disclosure of which would impair the competitive position of
22 the submitter and would make available information not otherwise publicly available.

23 **7. Audit.** The department may require an operator to submit an independent
24 financial audit of a drug take-back stewardship program.

25 **8. Collection.** This subsection applies to authorized collectors, mandatory pharmacy
26 collectors and collection sites.

27 A. A mandatory pharmacy collector shall participate in each drug take-back
28 stewardship program. A mandatory pharmacy collector shall prominently display
29 signage advertising covered drug collection to consumers and provide for the safe
30 collection of covered drugs through:

31 (1) On-site, publicly accessible and secure collection receptacles meeting federal
32 standards;

33 (2) Mail-back collection by prepaid envelopes as authorized by federal law and
34 regulation; and

35 (3) Other methods of collection approved by the United States Department of
36 Justice, Drug Enforcement Administration.

37 B. An operator shall notify all authorized collectors of the opportunity to serve as a
38 collection site for the drug take-back stewardship program. Except for mandatory
39 pharmacy collectors, participation of an authorized collector is voluntary.

1 C. A drug take-back stewardship program must include as a collection site each retail
2 pharmacy and hospital or clinic with an on-site pharmacy and each law enforcement
3 agency that volunteers to participate in the stewardship program without
4 compensation and is an authorized collector. An operator shall add the pharmacy,
5 hospital, clinic or law enforcement agency as a collection site in the stewardship
6 program no later than 90 days after the operator receives the offer to participate.

7 D. Mandatory pharmacy collectors and authorized collectors for a drug take-back
8 stewardship program shall provide information on covered drug collection and safe
9 drug disposal options to a consumer upon dispensing a covered drug.

10 E. As part of a drug take-back stewardship program, all collection requirements of
11 mandatory pharmacy collectors and authorized collectors, including, but not limited
12 to, collection receptacles, mail-back envelopes, educational materials and drug-
13 disposal-specific surveillance, must be provided by the operator free of charge to the
14 collectors.

15 **9. Third-party outreach assessment.** Every 2 years, a drug take-back stewardship
16 organization shall fund a 3rd-party assessment of the effectiveness of education and
17 outreach efforts under the drug take-back stewardship program. The methods and scope
18 of the assessment must include input by the department. The stewardship organization
19 shall make changes to the education and outreach efforts based on the results of the
20 assessment.

21 **10. Annual drug take-back stewardship program report.** Within 90 days after
22 the first full year of implementation, and annually thereafter, an operator shall submit to
23 the department a report describing the implementation of the drug take-back stewardship
24 program during the previous calendar year. The report must include at a minimum:

25 A. A list of manufacturers participating in the drug take-back stewardship program,
26 including current contact information;

27 B. The amount by weight of covered drugs collected, including the amount by
28 weight from each collection method used, both in total and by county;

29 C. Details regarding the drug take-back stewardship program's collection system,
30 including a list of collection sites with addresses; the number of mail-back envelopes
31 provided; locations where mail-back envelopes were provided, if applicable; dates
32 and locations of collection events held, if applicable; and the transporters and
33 disposal facility or facilities used;

34 D. Whether any safety or security problems occurred during collection,
35 transportation or disposal of covered drugs and, if so, completed and anticipated
36 changes to policies, procedures or tracking mechanisms to address the problem and
37 improve safety and security;

38 E. A description of the public education, outreach and evaluation activities
39 implemented to ensure that 60% of consumers are aware of the drug take-back
40 stewardship program after one year of stewardship program implementation, 70%
41 after 2 years, and 90% after 4 years in accordance with subsection 3, paragraph I. In
42 order to evaluate whether the consumer awareness goals are reached, every 2 years

1 the report must include the results of an assessment of the methods used for and
2 effectiveness of education and outreach efforts pursuant to subsection 9;

3 F. A description of how collected packaging was recycled to the extent feasible;

4 G. A description of the methods used to collect, transport and dispose of covered
5 drugs;

6 H. A summary of the drug take-back stewardship program's degree of success in
7 meeting goals for diversion rates, if applicable, and, if any goals have not been met,
8 what effort will be made to achieve those goals the following year;

9 I. An evaluation of the convenience of collection for people living in various regions
10 of the State;

11 J. The total cost of implementing the drug take-back stewardship program, including,
12 but not limited to, the stewardship program's annual expenditures, as determined by
13 an independent financial audit; and

14 K. Any recommendations for changes to the drug take-back stewardship program to
15 improve convenience of collection, consumer education and stewardship program
16 evaluation.

17 **11. Administration.** The department shall charge a reasonable fee to be paid by a
18 manufacturer or drug take-back stewardship organization for review of a drug take-back
19 stewardship plan. The department may establish a reasonable annual fee to cover the
20 actual costs for annual report review, oversight, administration and enforcement. Fees
21 established pursuant to this subsection may not exceed the greater of \$100,000 per year
22 and one percent of total drug take-back stewardship program costs as set forth in the
23 independent financial auditing report under subsection 10, paragraph J.

24 **12. Private right of action.** A manufacturer or a drug take-back stewardship
25 organization implementing an approved drug take-back stewardship plan in compliance
26 with the requirements of this section may bring a civil action against another
27 manufacturer or stewardship organization for damages when:

28 A. The plaintiff manufacturer or drug take-back stewardship organization incurs
29 more than \$3,000 in actual direct costs in collecting, handling or disposing of covered
30 drugs sold or offered for sale in the State by another manufacturer;

31 B. The manufacturer from whom damages are sought can be identified as the
32 manufacturer of the collected covered drugs from a brand or marking on the
33 discarded covered drug or from other information available to the plaintiff
34 manufacturer or drug take-back stewardship organization and does not operate a drug
35 take-back stewardship program in the State;

36 C. The plaintiff manufacturer or drug take-back stewardship organization submitted
37 a reimbursement request to another manufacturer or stewardship organization; and

38 D. The plaintiff manufacturer did not receive reimbursement within:

39 (1) Sixty days after the request for reimbursement under paragraph C, if the
40 plaintiff manufacturer or drug take-back stewardship organization did not request
41 an independent audit under subparagraph (2); or

